MIRXES-B (02629.HK): Enters Partnership with Affiliate of Thailand’s Largest Healthcare Group, and Secures Approval for Two At-home Test Kits

January 9，MIRXES-B (02629.HK) issued a voluntary announcement, declaring that it has achieved multiple business milestones in the Thai market. On December 15, 2025, the Company entered into a strategic cooperation with N Health, a medical solutions company under BDMS Group—the largest healthcare provider in Thailand. The collaboration aims to introduce advanced miRNA cancer screening technology to Thailand and gradually expand coverage to the Southeast Asian market.

Through this partnership, the Company’s miRNA testing solutions including GASTROClear™(gastric cancer screening product) and LUNGClear™(lung cancer screening product) will be made available in nearly 60 hospitals within N Health’s network, supporting the expansion of early cancer screening services in Thailand and Southeast Asia.

In addition, the Company announced that two of its at-home screening test kits—HELICORapid (Helicobacter pylori infection test) and FITRapid (fecal occult blood test)—have obtained approval from Thailand’s FDA in October and December 2025 respectively, and are officially launched in the Thai market on January 9, 2026. As pioneering products in the Thai market, these two kits feature an integrated design and will be distributed through modern trade channels and pharmacy networks, further expanding the Company’s footprint in the consumer health sector.

The Company stated that this partnership and the launch of new products mark a crucial step in its strategy to advance early cancer detection in Southeast Asia. The initiatives will help improve the accessibility of cancer screening in the region and support the Company’s expansion into consumer-facing health testing scenarios.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.